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Abstract The ADHD Under Treatment Observational
Research (AUTOR) study was a European prospective,
observational study that assessed factors associated with
changes in ADHD severity, estimated change from base-
line in quality of life (QoL), and characterized changes in
ADHD symptoms over a 2-year period as a function of
baseline treatment. The primary objective was to identify
factors associated with worsening in ADHD severity dur-
ing a 2-year follow-up period for subjects aged 6–17 years,
who were receiving the same pharmacotherapy for
3–8 months before enrollment and had a Clinical Global
Impression (CGI)-ADHD-Severity score of mild/lower and
a CGI-ADHD-Improvement score of improved/very much
improved. Multivariate logistic regression examined the
association of factors with worsening in ADHD. Mixed-
model repeated measures regression analyzed QoL in terms
of change from baseline in CHIP-CE PRF scores. There
were 704 subjects analyzed. Variables associated with
worsening ADHD severity were parental occupation,
poorer school outcomes, and use of psychoeducation;
baseline treatment was not significant. Among the sec-
ondary objectives, initial use of atomoxetine (vs. stimu-
lants) was associated with a significant improvement on the
CHIP-CE PRF total score, with an adjusted treatment dif-
ference of -6.0 (95 % CI -7.9, -4.1) at 24 months.
Additionally, the odds of stability (CGI-ADHD-S B 3 over
the 2-year period) were significantly lower for subjects
initially responding to stimulants compared with atomox-
etine (OR 0.5; 95 % CI 0.3, 0.8). ADHD symptom wors-
ening was associated with initial use of psychoeducation,
parental occupation, and poorer school outcomes.
Response to initial treatment with atomoxetine was asso-
ciated with improved QoL over 2 years.
Keywords Attention-deficit/hyperactivity disorder 
Atomoxetine  ADHD  Quality of life  Treatment 
Observational
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is char-
acterized by inattention, impulsivity, and hyperactivity and
is associated with other psychiatric comorbidities (Pliszka
2000; Spencer 2006). Patients are at a higher risk of
cigarette smoking, substance abuse (Daley 2004; Vansickel
et al. 2007), more traffic accidents (Barkley 1998; Weiss
et al. 1999), and criminality (Klein and Mannuzza 1991).
Adverse consequences persist through adolescence into
adulthood, including academic impairment, social dys-
function, poor self-esteem (Biederman et al. 2004), and
increased rates of suicide (Barbaresi et al. 2013). Thus, the
burden of illness associated with ADHD is high for
affected individuals, their families, and society (Leibson
and Long 2003).
Current treatments for ADHD include social, psycho-
logical, and behavioral interventions and pharmacotherapy.
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investigated in well-documented, short-term studies (Bie-
derman et al. 2004; Perwien et al. 2004). An important
question is whether there is a continued value of ADHD
pharmacotherapy treatment for subjects who had an initial
clinical response. Children and adolescents who responded
to open-label atomoxetine treatment maintained their
responses for up to 18 months (Michelson et al. 2004;
Buitelaar et al. 2007). Maintenance of response to ato-
moxetine in adults for up to 6 months has also been
demonstrated (Upadhyaya et al. 2013).
Most research on the efficacy of ADHD treatments has
been conducted within a clinical trial setting in which
subject eligibility is restricted by a large set of inclusion
and exclusion criteria. In clinical practice, however, the
subject population receiving ADHD medications has a
wider array of clinical comorbidities than allowed in most
clinical trials. Subjects may be prescribed various types of
treatment concomitantly, and these treatments may change
over time. Thus, it would seem that real-world outcomes
would be of considerable interest, but few naturalistic/ob-
servational studies have been conducted in pediatric sub-
jects with ADHD.
The Attention-Deficit/Hyperactivity Disorder Observa-
tional Research in Europe (ADORE) study, a 24-month,
observational study of approximately 1500 children and
adolescents in 10 European countries, analyzed long-term
treatment patterns (pharmacotherapy, psychotherapy,
combination of both, or no intervention) for ADHD and
the associated health outcomes for subjects following
their diagnosis and first treatment in European naturalistic
practice settings (Preuss et al. 2006). Subjects in the
ADORE pharmacotherapy treatment groups showed
greater improvement than those with nonpharmacother-
apy. This finding was similar to that of the Multimodal
Treatment Study of ADHD (MTA) (Jensen et al. 2007), a
randomized clinical study aimed at comparing the effects
of medication management, behavior therapy, a combi-
nation of medication and behavior therapies, and usual
community care over a 14-month period in the USA (The
MTA Cooperative Group 1999), with noninterventional
follow-ups at 3 and 8 years (Jensen et al. 2007; Molina
et al. 2009). Neither the MTA nor the ADORE study
assessed the changes in symptomatology after response to
treatment; rather, the focus of these studies was to fol-
low-up with subjects after their initial treatment to
determine whether that treatment was effective or inef-
fective. The AUTOR study was designed to augment the
findings of earlier maintenance clinical trials (Gillberg
et al. 1997; Michelson et al. 2004; Buitelaar et al. 2007)
by characterizing longer-term treatment patterns among
pharmacotherapy responders and factors associated with
loss of response in the clinical practice setting across
Europe.
The AUTOR study is a longitudinal, observational,
naturalistic study conducted in subjects from 6 to 17 years
old who are diagnosed with ADHD. The primary objective
was to identify the factors associated with an increase in
ADHD symptom severity during a 2-year follow-up period
in subjects who were responders and were stable on their
initial pharmacotherapy. Secondary objectives related to
effectiveness and tolerability were to describe the factors
associated with a decrease in ADHD symptom severity,
quality of life (QoL) changes, treatment patterns, factors
associated with relapse, factors associated with stability,
tolerability, and the duration of treatment effect during the
day associated with different pharmacotherapies.
Materials and methods
As the primary objective, characterizing factors associated
with worsening in ADHD symptoms, was associated with a
binary endpoint of worsening or no worsening, the study
protocol approximated a sample size of 900 patients using
a two-sided Chi-square test at a 5 % significance level in
order to have a 80 % power to detect a difference between
group 1 proportion p1 = 0.5 and group 2 proportion
p2 = 0.59. Slower than expected enrollment resulted in
704 patients in the analysis set, causing only a slight
increase in the minimum difference that could be detected
between the two group proportions (p1 = 0.5 and
p2 = 0.6).
Subjects
Physicians enrolled patients aged 6–17 years old who had
been diagnosed with ADHD and who had responded to
their first and current pharmacotherapy treatment for
3–8 months. Clinical responders were identified as having
a Clinical Global Impression-ADHD-Severity (CGI-
ADHD-S) score of mild or lower (CGI-ADHD-S B 3 at
study entry) and a Clinical Global Impression-ADHD-Im-
provement score (CGI-ADHD-I) of much improved or very
much improved (CGI-ADHD-I = 1 or 2) (Arnold et al.
2004) at the baseline observation compared to the time of
treatment initiation. Subjects were excluded if they had, in
the clinical judgment of the investigator, a pervasive
developmental disorder or were already participating in
another treatment study.
The requirement for treatment stability at study entry
increased the naturalistic character of the trial by ensuring
that treatment patterns were not altered due to participation
in the study. During AUTOR, subjects were allowed to
take any commercially available medication (including
combination therapy) or nonpharmacotherapy for the
treatment of ADHD; ADHD treatment could be
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discontinued or changed at any time, and subjects were
followed in the study, regardless of changes or discontin-
uation of their original ADHD treatment.
Subjects were informed as to the risks and benefits of
trial participation; their parents gave written consent and
they provided written assent for the use of their data, as
required by local regulations. The study was conducted in
accordance with the ethical principles of the Declaration of
Helsinki and was consistent with good clinical practices
and applicable local laws and regulations.
Procedure
Data were collected at naturally occurring visits for the
subjects, according to regular practice at the study site;
these visits were assigned to the closest of the following
observation windows: 0, (baseline), 3, 6, 9, 12, 18, and
24 months (from baseline), ± 6 weeks. Apart from base-
line confirmation of eligibility and capture of sub-
ject/family information and demographics, all other
assessments were performed at each visit.
Symptom severity was measured with the CGI-ADHD-S
and the ADHD Rating Scale-IV-Parent Version-Investi-
gator-completed (ADHDRS). ADHD symptom severity
worsening was defined as a C2-point increase from base-
line in CGI-ADHD-S score. A two-point worsening on
CGI-ADHD-S was included to identify clinically mean-
ingful relapse in the relapse prevention study of atomox-
etine (Michelson et al. 2004) and a lisdexamphetamine trial
(Coghill et al. 2014). A decrease in ADHD severity was
defined as a C2-point decrease in the CGI-ADHD-S from
one of the follow-up observations to any of the subsequent
observations.
Information on the use of pharmacotherapy and other
treatments for ADHD was collected at each visit. Phar-
macotherapy treatment classes at baseline were a priori
defined for analysis as stimulant, atomoxetine, other, and
combination. The combination class comprised subjects
taking more than one pharmacotherapy class. Subjects in
any treatment class could receive nonpharmacotherapy
sessions. A change in pharmacotherapy was defined as
moving from one class to another or changing to only
nonpharmacotherapy treatment. Discontinuation from
therapy was defined as no pharmacotherapy and no non-
pharmacotherapy for at least 4 weeks.
QoL changes over the 2-year period were measured by
the Child Health and Illness Profile, Child Edition-Parent
Report Form (CHIP-CE PRF) (Riley et al. 2001, 2004).
Four different definitions of relapse were used: (1)
increase of 50 % or greater on the ADHDRS total score and
an increase in the CGI-ADHD-S score of at least 2 points, (2)
increase of at least 50 % on the ADHDRS total score from
the baseline, (3) a CGI-ADHD-S score of at least markedly ill
(C5) at any post-baseline assessment, and (4) a minimum of a
2-point increase on the CGI-ADHD-S from baseline over 2
consecutive post-baseline assessments. Stability was defined
as CGI-ADHD-S of ‘‘mild’’ or lower (B3) over the entire
2-year period. Relapse definition 1 was used in the pivotal
maintenance of response study of atomoxetine (Michelson
et al. 2004) and a recent lisdexamphetamine maintenance of
response trial (Coghill et al. 2014). Relapse definition 2
included the ADHDRS symptom assessment only, and
relapse definition 4 required a repeated observation of
worsening to flag relapse.
Duration of treatment effect during the day associated
with different pharmacotherapies was measured by the
Global Impression of Perceived Difficulties (GIPD) scale
(Wehmeier et al. 2008).
Statistical analysis
General considerations
Analyses were exploratory. Two baseline treatment classes
(stimulant and atomoxetine) were compared with respect to
their effect on worsening of ADHD severity and other
secondary outcome/tolerability measures. All statistical
analyses were pre-specified in a Statistical Analysis Plan
that was approved before database lock. All statistical
analyses were performed using SAS version 9.2 (SAS
Institute, Inc., Cary, NC, USA). No corrections were made
for multiple comparisons.
Demographics and treatment compliance and patterns
Descriptive statistics were used to summarize subject
characteristics, total daily dose by baseline pharmacologi-
cal treatment group and by time point, compliance by
baseline pharmacological treatment group, number of ses-
sions per month by baseline nonpharmacological treatment
and time point, and time to first change/switch/discontin-
uation of therapy. The Kaplan–Meier method was used to
estimate the survival curves for time to first change/switch/
discontinuation of therapy and comparison between treat-
ment groups were conducted by a 2-sided log-rank test.
Subjects discontinuing the study without discontinuing
treatment were considered censored at the time of exiting
the study.
Primary outcome measure
Multivariate logistic regression was used to identify factors
associated with worsening in ADHD severity. A patient
was considered to have a worsening in ADHD severity if a
minimum of two points increase in the CGI-ADHD-S score
(vs. baseline CGI-ADHD-S score) was observed at any of
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the subsequent follow-up observations. The set of covari-
ates are listed in Table 1. Covariates that were noncorre-
lated (r\ 0.7) and statistically significant in univariate
logistic regression models (p\ 0.10) were included in the
full multivariate logistic models. The analysis plan allowed
for treatment to be included as a time-varying covariate
only if[25 % of patients switched their baseline medica-
tion; however, the proportion of patients switching treat-
ments was much lower so treatment was not included as a
time-varying covariate. Treatment compliance was inclu-
ded as a time-varying covariate in the multivariate models;
however, the addition of this covariate did not change the
model estimates and was dropped from the final model. In
addition, propensity scores (PS), estimated using multi-
variable logistic regression, were included in the models as
additional covariates to adjust for the probability of
receiving a specific treatment given the subject gender, age,
ADHD subtype, family history of ADHD, substance use,
psychiatric comorbidities and resource utilization baseline
variables. Logistic models with and without PS covariates
were estimated. For the final multivariable model, Type III
p values and adjusted odds ratios comparing each level
against an arbitrary baseline reference level and associated
95 % CI were calculated.
Secondary outcomes
Mixed models for repeated measures (MMRM) were used
to estimate adjusted differences between stimulant and
atomoxetine baseline treatments in relation to changes
from baseline for GIPD total scores and items and the
CHIP-CE PRF standardized total, domain, and subdomain
scores. The MMRMs contained baseline treatment, visit,
baseline treatment-by-visit and PS and baseline treatment-
by-PS interactions as independent variables and used an
unstructured covariance matrix to model the between-
Table 1 Covariates considered in the logistic regression modeling process for primary and secondary endpoints
Independent variables Categories Reference level
Baseline covariates
Gender Male versus female Female
Age 5–12 versus 13–18 13–18 years
ADHD subtype Hyperactive/impulsive or combined, inattentive Inattentive
Family history of ADHD Immediate family, extended family, no family history No family history
Substance use Yes (if smoked, used alcohol, or used illegal drugs) versus no substance use No substance use
Psychiatric comorbidities Current presence of Tourette’s Disorder, tics, anxiety, depression, conduct
disorder, oppositional defiant disorder, bipolar disorder, or psychosis versus no
current presence of 1 of these conditions
No current presence of
these comorbidities
Total number of contacts to
all healthcare providers
Continuous N/A
Origin West Asian, East Asian, Hispanic, Black or African-American, White White
Family setting Child lives with single biological parent, guardian, biological parents separately,
both biological parents, other
Other
Number of siblings Continuous N/A
Parental work status Working for pay full-time, part-time work, unemployed, keeping house Working for pay full-
time
Psychoeducation Yes, no No
ADHDRS total score Treated as continuous N/A
Parental occupation Elementary occupations; managers and senior officials; process, plant and machine
operatives; sales and customer service; caring, leisure and other personal service;





3 months prior to study
entry)
Not in school during the past 3 months, suspended from school, expelled from
school, or requested to change to a special need school; Some exclusion from




Propensity score Continuous N/A
Treatment Stimulant, atomoxetine Atomoxetine
Time-varying covariates
Compliance Never, Always, Occasionally, Some of the Time, Most of the Time Always
N/A nonapplicable, vs. versus
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subjects and within-subjects errors. Other covariates con-
sidered in the model were age, gender, ADHD subtype,
family history of ADHD, drug consumption, psychiatric
comorbidities, score at baseline, compliance at baseline,
tolerability at baseline, treatment satisfaction at baseline,
school outcomes at baseline, baseline bullying, and total
number of contacts to healthcare providers at baseline. Of
these covariates, only covariates found to be significant
(p\ 0.10) in a first-step model (including baseline treat-
ment, visit, baseline treatment-by-visit and PS, baseline
treatment-by-PS interactions, and the covariate of interest)
were retained in the final multivariable model. Multivariate
logistic regression models were used to estimate adjusted
odds ratios for variables associated with relapse and sta-
bility. The covariates were the same as those used in the
analysis of the primary outcome variable (Table 1).
Logistic regression models, with and without PS, and with
and without treatment compliance as time-varying covari-
ates, were estimated.
Tolerability
The number and percentage of subjects with solicited AEs
were calculated for each visit within the treatment class at
that visit. The effect of baseline treatment on AEs was
assessed with a logistic regression model for repeated
measures using a population-averaged GEE approach. GEE
models included baseline treatment, visit, treatment-by-
visit interaction, propensity score, and treatment-by-PS
interactions as independent variables. An unstructured
covariance matrix was used to model the between and
within subject errors. For each AE, adjusted odds ratios
between treatments at each visit and averaged over all
visits were estimated.
Results
Disposition, demographics, and baseline
characteristics
The AUTOR study was conducted at 74 study centers in
Denmark, Greece, Italy, Netherlands, Romania, Slovenia,
Sweden, and the UK. Subject enrollment began September
2008 and completed in February 2013. Practice settings
(93 % urban) were 4 % inpatient, 47 % outpatient, and
49 % a combination of both and were 8 % private, 68 %
public, and 24 % a combination of both.
The majority (86 %) of investigators were child psy-
chiatrists, and the remainder were neurologists, child neu-
rologists, and pediatricians with an average duration of
practice of 25 years. Of the 801 subjects who entered the
study, 704 met entry criteria and comprised the analysis
set. At baseline, 704 subjects were stable on and responsive
to the following medications: stimulants (N = 302 [48 %
methylphenidate and 53 % methylphenidate long-acting]),
atomoxetine (N = 395), other pharmacotherapies (N = 5
[60 % antipsychotics and 40 % other), or a drug combi-
nation (N = 2 [100 % methylphenidate long-acting and
atomoxetine]) (Table 2).
Of the 704 subjects in the study, the majority were
Caucasian (98.9 %) and male (81.5 %). Nearly 80 % of the
subjects completed the 2-year study. Table 3 summarizes
the physical characteristics, comorbidities, prior treatment
duration, and disposition of the sample. Figure 1 summa-
rizes the subjects by country. The majority of subjects were
recruited from Italy, Romania, and Greece, and the pattern
of allocation to treatment reflects the timing of medication
availability in those regions.
Treatment compliance and patterns
Treatment compliance was estimated by clinical staff at
each visit by selecting for how they took medication—
never, occasionally do, some of the time, most of the time,
and always. Treatment compliance was comparable across
baseline treatment groups, and it decreased throughout the
study with the highest compliance observed at baseline
(74.0 % always, 21.6 % most of the time, 2.3 % some of
the time, 1.2 % occasionally do, and 0.9 % never) and the
lowest compliance observed at Month 24 (65.1 % always,
26.1 % most of the time, 5.6 % some of the time, 1.8 %
occasionally do, and 1.4 % never). The average total daily
dose of medication showed no to minimal change over the
2 years of treatment for subjects who remained on
monotherapy. Average total daily doses at baseline and at
24 months are shown in Table 4.
Fewer subjects in the stimulant group at baseline
changed therapy (7.9 vs. 11.4 %), discontinued treatment
(13.2 vs. 14.9 %), or had a change of dose (17.9 vs.
23.3 %) versus subjects on atomoxetine at baseline. The
log-rank test showed that there was no statistical difference
between the treatments regarding time to any of these
events. Time until 5 % of the population had an event is
reported as the median time to event was not defined. As
determined by the Kaplan–Meier survival curves, the
estimated length in days and 95 % CI until 5 % of the
population had an event for stimulant-treated versus ato-
moxetine-treated subjects for time to first change of ther-
apy (Fig. 2) was 283.6 [153.8–565.3] days versus 269.6
[194.7–327.6] days, respectively. The estimated length in
days and 95 % CI until 5 % of the population had an event
for stimulant-treated versus atomoxetine-treated subjects
for time to first treatment discontinuation (Fig. 3) was
194.7 [92.9–286.6] days versus 166.8 [113.9–244.7] days.
The estimated length in days and 95 % CI until 5 % of the
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Table 2 Patient flow from
baseline to month eighteen
Analysis visit Stimulant Atomoxetine
Baseline N = 302 N = 395
3 Months
Discontinued at previous visits 10 5
Pharmacotherapy nonstimulant N/A 376
Pharmacotherapy stimulant 272 N/A
Drug combination 1 1
Present at further visits, did not attend current visit 19 13
6 Months
Discontinued at previous visits 14 18
Pharmacotherapy nonstimulant 2 342
Pharmacotherapy stimulant 256 3
Drug combination 1 2
Nonpharmacotherapy 1 4
No treatment for primary study condition 3 3
Present at further visits, did not attend current visit 25 23
9 Months
Discontinued at previous visits 22 26
Pharmacotherapy nonstimulant 2 326
Pharmacotherapy stimulant 231 7
Drug combination N/A 1
Nonpharmacotherapy 2 7
No treatment for primary study condition 7 11
Present at further visits, did not attend current visit 37 17
Discontinued after month 6 1 N/A
12 Months
Discontinued at previous visits 32 37
Pharmacotherapy nonstimulant 8 309
Pharmacotherapy stimulant 231 12
Drug combination 2 5
Nonpharmacotherapy 3 8
No treatment for primary study condition 8 14
Present at further visits, did not attend current visit 16 9
Discontinued after month 6 1 N/A
Discontinued after month 9 N/A 1
Completed at previous visits 1 N/A
18 Months
Discontinued at previous visits 44 42
Pharmacotherapy nonstimulant 8 293
Pharmacotherapy stimulant 217 15
Drug combination 2 3
Nonpharmacotherapy 3 12
No treatment for primary study condition 9 20
Present at further visits, did not attend current visit 17 9
Discontinued after month 6 1 N/A
Discontinued after month 9 N/A 1
Completed at previous visits 1 N/A
24 Months
Discontinued at previous visits 67 62
Pharmacotherapy nonstimulant 9 265
Pharmacotherapy stimulant 206 17
300 V. Haynes et al.
123
population had an event for stimulant-treated versus ato-
moxetine-treated subjects for time to first dose change
(Fig. 4) was 89.9 [76.9–105.9] days versus 93.9
[81.9–126.8] days, respectively.
Few subjects (15 [2.1 %] at 24 months) switched to only
receive nonpharmacotherapy during the study; however,
over a third of subjects were receiving some form of
nonpharmacotherapy at study entry. There was little
change in nonpharmacological treatment participation over
the course of 24 months (Table 4).
Primary outcome measure
Figure 5 presents the results from the multivariate
logistic model estimated without PS and/or time-varying
covariates. School outcome was statistically significant
(Type III p\ 0.001), with the odds of an increase in
ADHD symptoms severity being significantly greater for
subjects who had some exclusion from school lessons
and/or were in a special education program than for
subjects who were manageable in a classroom environ-
ment (odds ratio [95 % CI]; 2.7 [1.5–4.8]; p\ 0.001).
The odds of an increase in ADHD symptom severity
were significantly greater in subjects who were not in
school during the past 3 months, who were suspended
from school, who were expelled from school, and/or who
were requested to change to a special need school than in
subjects who were manageable in a classroom environ-
ment at baseline (odds ratio [95 % CI]; 5.0 [1.4–18.2];
p = 0.015). Baseline parental occupation was also sta-
tistically significant (Type III p = 0.003) overall; how-
ever, none of the specific pairwise comparisons between
parental occupations to the arbitrary reference group
(managers and senior officials) were statistically signifi-
cant. The odds of an increase in ADHD symptom
severity were also significantly greater for subjects who
received psychoeducation at baseline than for subjects
who did not receive it at baseline (odds ratio [95 % CI];
2.2 [1.3–3.7]; p = 0.004).
Secondary outcome measures
For the secondary outcome measures, like the primary
outcome analysis, the estimates from the logistic regression
model including additional PS covariates and/or time-
varying covariates were similar to the models without PS
and without time-varying covariates. Therefore, results
from the model without a PS and without time-varying
covariates are reported. Factors associated with a decrease
in ADHD symptom severity showed a statistically signifi-
cant effect of parental work status (Type III p = 0.001),
with the odds of a decrease in ADHD symptom severity
being significantly greater for subjects who had parents
who worked part-time at baseline than for those who had
parents who worked for full-time pay at baseline (odds
ratio [95 % CI]; 11.7 [3.4–39. 9]; p\ 0.001).
The MMRM analysis of changes from baseline in CHIP-
CE PRF standardized total scores showed a statistically
significant baseline treatment-by-visit interaction (Type III
p\ 0.001). At Months 3, 9, 12, 18, and 24, subjects who
entered the study on stimulants had significantly less
improvement from baseline in CHIP-CE PRF standardized
total scores than subjects who entered the study on ato-
moxetine (Fig. 6). The estimates of the adjusted differ-
ences (least-square means) between subjects who entered
on stimulants and atomoxetine were increasing over time.
In particular, the maximum difference between baseline
treatment groups was -6.0 (95 % CI -7.9, -4.1) at
24-month post-baseline.
Logistic regression models were used to study the
association of different risk factors with each of the 4
protocol definitions of relapse (Table 5). The majority of
subjects did not relapse at any time during the 2-year study.
Higher baseline ADHDRS total score was associated with a
decreased probability of relapse for the definitions that
included ADHDRS total as a relapse criterion and an
increased probability of relapse according to the definition
based only on the CGI-ADHD-S. The odds of relapse were
significantly greater for subjects who entered the study on
Table 2 continued
Analysis visit Stimulant Atomoxetine
Baseline N = 302 N = 395
Drug combination 1 6
Nonpharmacotherapy 3 12
No treatment for primary study condition 3 31
Discontinued after month 6 1 N/A
Discontinued after month 9 N/A 1
Discontinued after month 18 4 N/A
Completed at previous visits 8 1
N number of subjects, N/A not applicable
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stimulants, who had received psychoeducation at baseline,
who had a family history of ADHD, or who had a
comorbidity. The odds of relapse were significantly
increased for subjects not manageable in a classroom
environment.
Factors associated with stability (Table 5) showed a
statistically significant effect of baseline school outcome
(Type III p\ 0.001), with the odds of stability being sig-
nificantly lower for subjects who had some exclusion from
school lessons or were in a special education program at
baseline than for those who were manageable in a class-
room environment at baseline. In addition, the odds of
stability were significantly lower for subjects who entered
the study on stimulants versus those who entered on ato-
moxetine and for subjects who received psychoeducation
versus those who did not. The odds of stability decreased
by a factor of 0.98 when the baseline ADHDRS total score
increased 1 unit, keeping the other variables constant.
There was a significant effect of baseline parental occu-
pation in the multivariate model with or without time-
varying covariates added (Type III p\ 0.001), but the
comparison of subjects who had parents in elementary
occupations versus those whose parents were managers and




disposition, and prior treatment
duration




Physical characteristics, mean (SD)
Age 10.9 (2.6) 10.6 (2.8)
Height 145.0 (16.6) 143.1 (17.2)
Weight 40.1 (15.2) 39.7 (15.8)
BMI 18.5 (3.6) 18.7 (3.9)
ADHD subtype
Predominantly inattentive, n (%) 42 (13.9) 62 (15.7)
Predominantly hyperactive impulsive, n (%) 21 (7.0) 40 (10.1)
Combined, n (%) 239 (79.1) 293 (74.2)
ADHD severity
CGI-ADHD-S, mean (SD) 2.6 (0.50) 2.5 (0.60)
ADHDRS total score, mean (SD) 25.1 (11.40) 22.8 (11.81)
ADHDRS Inattentive Subscale, mean (SD) 13.3 (6.07) 12.5 (6.00)
ADHDRS Hyperactivity-Impulsivity Subscale, mean (SD) 11.8 (6.28) 10.3 (6.82)
Psychiatric comorbidities, n (%)
Anxiety 24 (7.9 %) 82 (20.9 %)
Depression 10 (3.3 %) 19 (4.8 %)
Conduct disorder 31 (10.3 %) 43 (10.9 %)
Oppositional defiant disorder 88 (29.1 %) 108 (27.5 %)
Tourette’s syndrome 1 (0.3 %) 1 (0.3 %)
Tics 13 (4.3 %) 22 (5.6 %)
Coordination problems 28 (9.3 %) 28 (7.1 %)
Dyslexia 51 (16.9 %) 89 (22.6 %)
Other learning disorders 90 (29.8 %) 137 (34.9 %)
Bipolar disorder 1 (0.3 %) 0 (0.0 %)
Psychosis 1 (0.3 %) 0 (0.0 %)
Obsessive compulsive disorder 2 (0.7 %) 3 (0.8 %)
Subject disposition, n (%)
Completed 223 (73.8 %) 325 (82.3 %)
Discontinued 79 (26.2 %) 70 (17.7 %)
Caregiver decision 27 (8.9 %) 41 (10.4 %)
Loss to follow-up 26 (8.6 %) 15 (3.8 %)
Subject decision 15 (5.0 %) 12 (3.0 %)
Physician decision 11 (3.6 %) 2 (0.5 %)
Duration of baseline treatment (months), mean (SD) 4.9 (1.5) 5.0 (1.5)
N number of subjects, n number of affected subjects, SD standard deviation
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model with time-varying covariates added (odds ratio
[95 % CI]; 4.2 [1.3–14.0]; p = 0.019). When the logistic
regression model included PS, the results were generally
similar to the logistic regression without PS with one
exception: The odds of stability estimated with the model
that included PS were significantly lower in subjects with
at least one psychiatric comorbidity than in subjects with-
out a psychiatric comorbidity (odds ratio [95 % CI]; 0.5
[0.3–0.9]; p = 0.014), whereas the odds ratio for stability
was not significant in the model that did not include PS
(Table 5).
For the GIPD total score, the adjusted difference
between stimulants and atomoxetine averaged over the
2-year period was statistically significant (estimate [95 %
CI]; 0.3 [0.1–0.4]; p\ 0.001), with patients who entered
the study on stimulants being more likely to have investi-
gator-perceived difficulties (i.e., higher GIPD total scores)
than patients who entered on atomoxetine at all post-
baseline time points (Month 3 [LS mean change from
baseline stimulant vs. atomoxetine; -0.1 vs. -0.3;
p = 0.014]; Month 6 [-0.2 vs. -0.4; p = 0.048], Month 9
[-0.2 vs. -0.4; p = 0.006]; Month 12 [-0.1 vs. -0.4;
p = 0.005]; Month 18 [-0.1 vs. -0.5; p\ 0.001]; and
Month 24 [-0.1 vs. -0.6; p\ 0.001]). Similar results
were observed for the estimated averaged difference
between stimulants and atomoxetine when the other 3
GIPD questions were analyzed using the MMRM: ‘‘Diffi-
culty during school’’ (Type III p\ 0.001), ‘‘Difficulty
during homework’’ (Type III p\ 0.001), and ‘‘Difficulty
over the entire day including night’’ (Type III p = 0.010).
MMRM estimates for the treatment-by-visit interaction
were not statistically significant for the 2 GIPD questions
‘‘Difficulty in morning’’ (Type III p = 0.411) and ‘‘Diffi-
culty in evening’’ (Type III p = 0.971), indicating a con-






























Fig. 1 Countries participating in AUTOR










Average total daily dose, mg/kg, mean (SD) 0.5 (0.2)a, 0.8 (0.3)b 1.0 (0.3) 0.5 (0.3)a, 0.9 (0.3)b 1.1 (0.3)
Average total daily dose, mg, mean (SD) 19.5 (9.7)a, 31.2 (12.1)b 37.7 (16.7) 20.3 (10.6)a, 32.2 (11.9)b 39.9 (17.0)
At least one nonpharmacological treatment, n (%) 91 (30.1) 156 (39.5) 88 (29.1) 158 (40.0)
Psychoeducation programs, n (%) 36 (11.9) 52 (13.2) 37 (12.3) 53 (13.4)
Counseling, n (%) 37 (12.3) 51 (12.9) 30 (9.9) 52 (13.2)
Cognitive behavioral therapy, n (%) 20 (6.6) 29 (7.3) 23 (7.6) 36 (9.1)
Family therapy, n (%) 2 (0.7) 11 (2.8) 2 (0.7) 17 (4.3)
Psychodynamic therapy, n (%) 1 (0.3) 3 (0.8) 7 (2.3) 10 (2.5)
Educational interventions in school, n (%) 21 (7.0) 24 (6.1) 21 (7.0) 35 (8.9)
Speech therapy, n (%) 7 (2.3) 20 (5.1) 7 (2.3) 26 (6.6)
Occupational therapy, n (%) 2 (0.7) 3 (0.8) 2 (0.7) 5 (1.3)
Relaxation techniques, n (%) 0 (0.0) 2 (0.5) 0 (0.0) 2 (0.5)
Hypnosis, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Psychomotor/physiotherapy, n (%) 6 (2.0) 13 (3.3) 7 (2.3) 10 (2.5)
EEG biofeedback, n (%) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Herbal/homeopathy, n (%) 0 (0.0) 2 (0.5) 0 (0.0) 1 (0.3)
Diet exclusion, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diet supplement, n (%) 1 (0.3) 0 (0.0) 1 (0.3) 0 (0.0)
Other, n (%) 2 (0.7) 8 (2.0) 3 (1.0) 9 (2.3)
EEG electroencephalography, n number of affected subjects, SD standard deviation
a Methylphenidate
b Methylphenidate long-acting
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Fig. 2 Kaplan–Meier plot for
time to first change of therapy
Fig. 3 Kaplan–Meier plot for
time to first treatment
discontinuation
Fig. 4 Kaplan–Meier plot for
time to first dose change
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2-year period. The estimated average treatment effect for
each of these GIPD questions showed that patients who
entered the study on stimulants were more likely to have
investigator-perceived difficulties in the morning (estimate
[95 % CI]; 0.3 [0.2–0.5]; p\ 0.001) and in the evening
(0.3 [0.1–0.4]; p\ 0.001) than patients who entered on
atomoxetine.
Tolerability
Overall, the percentages of solicited AEs were low and
generally decreased throughout the course of the study for
subjects who entered the study on stimulants or atomox-
etine (Table 6).
The GEE logistic regression analysis indicated that the
treatment-by-visit interactions for abdominal pain, fatigue,
and headache were not statistically significant. The esti-
mates of the odds ratios averaged over all visits indicated
that patients who received stimulants at baseline were less
likely to experience abdominal pain (averaged odds ratio
[95 % CI]; 0.5 [0.3–0.7]; p = 0.002); fatigue (averaged
odds ratio [95 % CI]; 0.4 [0.2–0.9]; p = 0.018); and
headache (averaged odds ratio [95 % CI]; 0.4 [0.3–0.7];
p\ 0.001). The baseline treatment-by-visit interactions
were statistically significant for decreased appetite (Type
III p = 0.05) and insomnia (Type III p = 0.017). For
decreased appetite, there was a statistical difference in the
odds of having decreased appetite only at the 24-month
Fig. 5 Factors associated with an increase in symptom severity in
subjects with attention-deficit/hyperactivity disorder (from a multi-
variate logistic regression model). For each factor, adjusted odds
ratios comparing each level against the baseline reference level and
associated 95 % CI and Type III p values are presented. Additionally,
for factors with more than 2 levels, corresponding homogeneity Type
III p values are also shown. Estimates from the logistic regression
model that included propensity scores and/or treatment compliance as
time-varying covariates as additional adjusting factors were similar to
the models without these additional adjustments. Abbreviations: 0
school outcome of manageable in a classroom environment; 1 school
outcome of some exclusion from school lessons and/or in a special
education program, 2 school outcome of not in school during the past
3 months, suspended from school, expelled from school, and/or
requested to change to a special need school, CI confidence interval,
LL lower limit, UL upper limit, vs. versus
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visit, with greater odds for subjects receiving stimulants at
baseline (odds ratio [95 % CI]; 3.3 [1.5–7.1]; p = 0.002).
For insomnia, a statistically significant difference was
observed between baseline treatment groups only at Month
12 with the odds of having insomnia being significantly
lower in the group who received stimulants at baseline
(odds ratio [95 % CI]; 0.5 [0.3–0.98]; p = 0.044).
Discussion
This study characterizes factors associated with an increase
in ADHD symptom severity during a 2-year follow-up
period in subjects who were responders and stable on their
first pharmacotherapy. In contrast to the magnitude of
switching observed in the ADORE study (Preuss et al.
2006), stability continued for the vast majority of subjects
who were stable on their ADHD treatment for 3–8 months.
Baseline treatments were maintained, there was minimal
switching or changes in dose, and compliance was good.
This difference might be due to ADORE being a study of
patients newly initiated to treatment, while AUTOR was a
study of treatment responders.
School outcome and parental occupation at baseline
were identified as factors associated with an increase in
ADHD symptom severity. Symptom severity was more
likely to increase in subjects with a negative school out-
come at baseline (vs. less negative school outcome). The
effect of baseline parental occupation on ADHD symptom
severity was less clear.
Psychoeducation at baseline was identified as a factor
associated with an increase in ADHD symptom severity,
which may be due to unmeasured confounding factors (i.e.,
variability in administration of psychoeducation sessions).
Conversely, this outcome could be related to an earlier
onset and to persistent ADHD symptoms, as European
guidelines recommend beginning ADHD treatment with
nonpharmacotherapy before initiating pharmacotherapy
treatment. Similarly, ADORE investigators found that
subjects initiated on psychotherapy and those who added
psychotherapy to existing pharmacotherapy had a signifi-
cant worsening of symptoms; this effect was most evident
for psychoeducation counseling. Psychoeducation may
have a deleterious effect if administered prior to a subject
being stabilized on pharmacotherapy (Falissard et al.
2010). Details about the type of psychoeducation were not
captured in this study, and the relative proportion of
patients who received psychoeducation was small; future
studies are needed to clarify this finding.
A secondary analysis identified parental work status at
baseline as a significant factor, with symptom severity
being more likely to improve in subjects whose parents
worked part-time; this could reflect these parents having
greater ability to provide additional support to ensure
medication compliance and be involved in nonpharma-
cotherapeutic interventions.
When factors associated with the most stringent criteria
of relapse (i.e., an increase of 50 % or greater on the
ADHDRS total score and an increase in the CGI-ADHD-S
score of at least 2 points) were examined, relapse was more
likely to occur in subjects who received psychoeducation
and subjects with higher baseline ADHDRS total scores.
These two factors were most consistently associated with
relapse, regardless of the definition. Worse baseline school
outcomes, prior family history of ADHD, and presence of
certain psychiatric comorbidities were associated with
relapse only when it was measured based on the CGI-
ADHD-S. Analysis of factors associated with stability
showed that subjects who entered the study on stimulants
were less likely to maintain their initial response than those
who entered the study on atomoxetine; subjects with higher
baseline ADHDRS total scores were less likely to maintain
their initial response. The overall relapse rates were much
lower than in the initial phase of the relapse prevention trial
of atomoxetine (Michelson et al. 2004), possibly due to the
longer response period required for entry into the AUTOR
study. The observed relapse rates during the continuation
period of the relapse prevention trial of atomoxetine
(Buitelaar et al. 2007) are comparable to those observed in
AUTOR.
Additional secondary analyses showed that subjects who
entered the study on stimulants reported significantly lower
QoL, as measured by the CHIP-CE PRF than subjects who
entered the study on atomoxetine over 2 years. This dif-
ference was most noted in the satisfaction and comfort
domains. Among treatment-naı¨ve patients randomized to
Fig. 6 Least-squares mean change from baseline in the Child Health
and Illness Profile, Child Edition-Parent Report Form total score from
the longitudinal mixed-model repeated measures regression. Abbre-
viations: CHIP-CE PRF Child Health and Illness Profile-Child
Edition, Parent Report Form, LS least squares
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treatment with atomoxetine versus other ADHD pharma-
cotherapy (comprised mostly of patients taking methyl-
phenidate), atomoxetine-treated patients had significantly
lower improvement on the CHIP-CE achievement domain
at 6 months, but there was no significant difference
between treatments at 12 months in this domain (Fuentes
et al. 2013). The CHIP-CE total score was not computed by
Fuentes et al. The difference in their finding of improve-
ment in CHIP-CE domain scores for the other ADHD
pharmacotherapy may be due to a difference in study
population, as they examined patients who were naı¨ve to
treatment and as our study was comprised of 3- to 8-month
treatment responders. The continued improvement in QoL
for patients initiated on atomoxetine differs slightly from
the findings of the relapse prevention trial (Michelson et al.
2004) in which this outcome was measured with the Child
Health Questionnaire. These investigators found that under
blinded conditions, maintenance of treatment with ato-
moxetine was associated with significantly less worsening
of QoL than was removal of treatment.
Subjects who entered as responders to stimulants had
greater investigator-perceived difficulties in the morning,
during school, during homework, over the entire day, and
in the evening as measured by the GIPD when compared
with subjects who entered as responders to atomoxetine.
Limitations
As an observational trial, subjects were not randomized to
treatment, and treatment decisions were left to the inves-
tigator and subject; thus, treatment comparisons are subject
to bias and confounding. Propensity scores were used to
adjust for the probability of receiving one treatment or
another, depending on differences in subject baseline
characteristics; however, differences between treatment
groups cannot be considered causal.
The study enrolled subjects who had responded to an
initial 3–8 months of treatment with ADHD medication;
therefore, the results generalize to that population rather
than to all treated ADHD subjects. Additionally, patients
Table 6 Percentage of solicited
adverse events that interfered
with subjects’ functioning or




N (% [95 % CI])
Stimulant at baseline
N (% [95 % CI])
Atomoxetine at baseline
N (% [95 % CI])
Baseline N = 704 N = 302 N = 395
Abdominal pain 6 (0.9 [0.3–1.8]) 3 (1.0 [0.2–2.9]) 3 (0.8 [0.2–2.2])
Changes in personality 2 (0.3 [0.0–1.0]) 2 (0.7 [0.1–2.4]) 0
Decreased appetite 27 (3.8 [2.5–5.5]) 7 (2.3 [0.9–4.7]) 20 (5.1 [3.1–7.7])
Fatigue 5 (0.7 [0.2–1.6]) 1 (0.3 [0.0–1.8]) 4 (1.0 [0.3–2.6])
Headaches 9 (1.3 [0.6–2.4]) 3 (1.0 [0.2–2.9]) 6 (1.5 [0.6–3.3])
Insomnia 14 (2.0 [1.1–3.3]) 4 (1.3 [0.4–3.4]) 10 (2.5 [1.2–4.6])
Sleepiness 3 (0.4 [0.1–1.2]) 2 (0.7 [0.1–2.4]) 1 (0.3 [0.0–1.4])
Month 12 N = 607 N = 252 N = 348
Abdominal pain 4 (0.7 [0.2–1.7]) 1 (0.4 [0.0–2.2]) 3 (0.9 [0.2–2.5])
Changes in personality 3 (0.5 [0.1–1.4]) 1 (0.4 [0.0–2.2]) 2 (0.6 [0.1–2.1])
Decreased appetite 11 (1.8 [0.9–3.2]) 3 (1.2 [0.2–3.4]) 8 (2.3 [1.0–4.5])
Fatigue 0 0 0
Headaches 9 (1.5 [0.7–2.8]) 2 (0.8 [0.1–2.8]) 7 (2.0 [0.8–4.1])
Insomnia 9 (1.5 [0.7–2.8]) 5 (2.0 [0.6–4.6]) 4 (1.1 [0.3–2.9])
Sleepiness 0 0 0
Month 24 N = 559 N = 222 N = 331
Abdominal pains 1 (0.2 [0.0–1.0]) 0 1 (0.3 [0.0–1.7])
Changes in personality 1 (0.2 [0.0–1.0]) 1 (0.5 [0.0–2.5]) 0.0
Decreased appetite 3 (0.5 [0.1–1.6]) 1 (0.5 [0.0–2.5]) 2 (0.6 [0.1–2.2])
Fatigue 0 0 0
Headaches 2 (0.4 [0.0–1.3]) 1 (0.5 [0.0–2.5]) 1 (0.3 [0.0–1.7])
Insomnia 4 (0.7 [0.2–1.8]) 2 (0.9 [0.1–3.2]) 2 (0.6 [0.1–2.2])
Sleepiness 0 0 0
CI confidence interval, MPH methylphenidate, N number of subjects
a No solicited adverse events that interfered with subjects functioning or health-related quality of life were
reported for treatment categories other pharmacotherapies (N = 5 [60 % antipsychotics and 40 % other), or
a drug combination (N = 2 [100 % MPH long-acting and atomoxetine])
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were recruited within practices where they were treated;
thus, the physician population reflects the real-world
treatment patterns for ADHD in these European countries.
The majority of subjects were recruited from Italy,
Romania, and Greece. and the pattern of allocation to
treatment reflects the timing of medication availability in
those regions; therefore, factors associated with ADHD
worsening are driven by the cultural, social, and economic
factors of those countries during that period.
The AEs conclusions are limited because subjects had
been on the same therapy for 3–8 months, which led to a
lower rate of AEs overall than would be expected in
patients who initiated on pharmacotherapy. Additionally,
information was solicited only for specific events common
with these treatments. AUTOR was not designed to char-
acterize long-term tolerability with these medications.
In conclusion, in this observational study of more than
700 European children and adolescents with ADHD who
were 3- to 8-month responders to their first pharma-
cotherapy, worsening of symptoms was associated with the
initial use of psychoeducation, parental occupation, and
poorer school outcomes, but not to initial treatment
administered; however, having achieved treatment
response for a 3- to 8-month period on atomoxetine was
associated with improved QoL and ADHD symptom sta-
bility. AUTOR extends the ADHD relapse prevention
studies by characterizing the performance of pharma-
cotherapy for responders in a naturalistic setting.
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